The vulnerable endothelium: priming the vascular endothelium for thrombosis with unfractionated heparin: biologic plausibility for observations from the Superior Yield of the New Strategy of Enoxaparin, Revascularization and GlYcoprotein IIb/IIIa Inhibitors (SYNERGY) trial.
Becker
Richard C
RC
D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology; D003327:Coronary Disease / Q000150:complications / Q000188:drug therapy; D004347:Drug Interactions; D004730:Endothelium, Vascular / Q000187:drug effects*; D017984:Enoxaparin / Q000008:administration & dosage / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D006493:Heparin / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology; D006801:Humans; D008074:Lipoproteins / Q000378:metabolism; D015201:Meta-Analysis as Topic; D008954:Models, Biological; D009203:Myocardial Infarction / Q000209:etiology / Q000517:prevention & control; D011292:Premedication; D016032:Randomized Controlled Trials as Topic; D019851:Thrombophilia / Q000139:chemically induced*; D013927:Thrombosis / Q000517:prevention & control*; D014657:Vasculitis / Q000139:chemically induced / Q000150:complications
D000925:Anticoagulants; D017984:Enoxaparin; D005343:Fibrinolytic Agents; D008074:Lipoproteins; C051928:lipoprotein-associated coagulation inhibitor; D006493:Heparin